Miruvor
ME/CFS Partial

JAK1 inhibitor Rinvoq quickly returns severely ill ME/CFS patient to health - Parts I and II

Condition
ME/CFS
At worst
Not stated
Ill for
Not stated
Published
May 2025

Summary

Took Rinvoq (upadacitinib) for two months without stating a dose, and describes it as not an easy drug to take. The gains were concentrated in the autonomic nervous system: orthostatic intolerance normalised with no further blood pressure drop or pre-syncope on standing, temperature regulation and appetite returned to normal after feeling famished most of the time, severe insomnia gave way to a normal sleep pattern, and stamina improved somewhat. The improvements emerged after she stopped the drug rather than while taking it, and had held for five months at the time of writing. Exertion intolerance remained, with roughly a day of PEM if she overdid things.

Read it in their words

forums.phoenixrising.me

What they credit

Credits JAK inhibitors (Rinvoq, baricitinib).

Symptoms mentioned

Symptoms: Brain fog, POTS & dysautonomia, Post-exertional malaise, Sleep problems, Temperature regulation.

Similar stories

  • Monoclonal antibodies article comments (Chris)

    Partial Long COVID SevereIll 9 months healthrising.org Dec 2025

    Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…

  • Filgotinib (JAK1 inhibitor) - future of CFS/ME treatment

    Near-full ME/CFS ModerateIll 3 years forums.phoenixrising.me Sep 2025

    Took filgotinib 200mg for three days in early 2023, after about three years of suspected ME/CFS that at its worst left him housebound, able to walk ten minutes before needing hours of rest and to sit upright only twenty minutes at a stretch while working…

  • Three clinical trials for Long COVID are testing JAK inhibitors (unnamed)

    Substantial Long COVID thesicktimes.org Aug 2025

    Credits upadacitinib. An unnamed patient had long COVID and reports a substantial improvement. Other two on the same drug worsened over six weeks.

  • Three clinical trials for Long COVID are testing JAK inhibitors (Jen)

    Full recovery Long COVID SevereEffect faded thesicktimes.org Aug 2025

    Jen took the JAK inhibitor upadacitinib (Rinvoq) for 66 days starting December 2023 before stopping early due to profound weakness and paralyzing fatigue with no apparent benefit while on the drug. She had suffered from severe myalgic encephalomyelitis for…